Avinger (NASDAQ:AVGR) Earns “Buy” Rating from Aegis

Avinger (NASDAQ:AVGR)‘s stock had its “buy” rating restated by analysts at Aegis in a research report issued to clients and investors on Monday, AnalystRatings.com reports. They currently have a $1.40 price target on the medical device company’s stock. Aegis’ target price points to a potential upside of 352.34% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Zacks Investment Research raised shares of Avinger from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research report on Friday, April 17th. LADENBURG THALM/SH SH lowered Avinger from a “buy” rating to a “neutral” rating in a report on Monday, April 13th.

Shares of AVGR stock opened at $0.31 on Monday. Avinger has a twelve month low of $0.24 and a twelve month high of $3.49. The company has a current ratio of 1.11, a quick ratio of 0.85 and a debt-to-equity ratio of 0.89. The stock has a fifty day simple moving average of $0.38 and a two-hundred day simple moving average of $0.62. The stock has a market capitalization of $9.69 million, a price-to-earnings ratio of -0.12 and a beta of 1.25.

Avinger (NASDAQ:AVGR) last released its quarterly earnings data on Wednesday, May 13th. The medical device company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Avinger had a negative net margin of 211.96% and a negative return on equity of 270.15%. The firm had revenue of $2.26 million during the quarter. Research analysts predict that Avinger will post -0.95 EPS for the current fiscal year.

An institutional investor recently bought a new position in Avinger stock. Sabby Management LLC purchased a new stake in Avinger Inc (NASDAQ:AVGR) during the first quarter, according to its most recent 13F filing with the SEC. The firm purchased 568,400 shares of the medical device company’s stock, valued at approximately $236,000. Avinger makes up 0.1% of Sabby Management LLC’s holdings, making the stock its 24th largest holding. Sabby Management LLC owned 1.93% of Avinger at the end of the most recent quarter. 7.34% of the stock is currently owned by institutional investors.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Featured Article: What is meant by a buy rating?

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.